MetLife Investment Advisors LLC lowered its stake in Viking Therapeutics Inc (NASDAQ:VKTX) by 15.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,602 shares of the biotechnology company’s stock after selling 5,062 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Viking Therapeutics were worth $219,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in shares of Viking Therapeutics by 12.0% in the 3rd quarter. Wells Fargo & Company MN now owns 65,810 shares of the biotechnology company’s stock worth $1,146,000 after purchasing an additional 7,037 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Viking Therapeutics by 11.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 385,484 shares of the biotechnology company’s stock worth $6,714,000 after purchasing an additional 39,455 shares in the last quarter. BlackRock Inc. increased its stake in shares of Viking Therapeutics by 14.0% in the 3rd quarter. BlackRock Inc. now owns 3,349,901 shares of the biotechnology company’s stock worth $58,355,000 after purchasing an additional 411,256 shares in the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of Viking Therapeutics in the 3rd quarter worth $2,516,000. Finally, Pacer Advisors Inc. purchased a new stake in shares of Viking Therapeutics in the 3rd quarter worth $331,000. 65.35% of the stock is owned by institutional investors and hedge funds.
VKTX has been the subject of several recent analyst reports. BidaskClub raised shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 target price on shares of Viking Therapeutics in a report on Thursday, April 11th. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a report on Friday, March 29th. Svb Leerink raised shares of Viking Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $10.00 to $21.00 in a report on Friday, March 29th. Finally, Maxim Group dropped their target price on shares of Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $22.54.
Shares of Viking Therapeutics stock opened at $8.82 on Friday. The firm has a market capitalization of $635.29 million, a P/E ratio of -22.05 and a beta of 2.75. Viking Therapeutics Inc has a fifty-two week low of $3.69 and a fifty-two week high of $24.00.
Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. On average, analysts expect that Viking Therapeutics Inc will post -0.45 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2019/04/21/viking-therapeutics-inc-vktx-shares-sold-by-metlife-investment-advisors-llc.html.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Featured Article: What is net income?
Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics Inc (NASDAQ:VKTX).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.